Gilead-JPM-20240108.pdf

1、2024:A Year of Clinical CatalystsJ.P.Mor ga n H ea lt h ca r e C on fer en ce8 Ja n u a r y 2 0 2 4Statements included in this presentation that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.Gilead cautionsreade

2、rs that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially.These risks and uncertainties include those relating to:Gileads abilityto achieve its anticipated full year 2023 financial results,including as a result of the uncer

3、taintyof the amount and timing of Veklurysales;Gileads abilityto make progress on anyofitslong-termambitionsorstrategicprioritieslaidoutinitscorporatestrategy;Gileadsabilitytoaccelerateorsustainrevenuesforitsvirology,oncologyandotherprograms;Gileadsabilitytorealizethepotentialbenefitsofacquisitions,

4、collaborationsorlicensingarrangements,includingGileadsabilitytoidentifysuitabletransactionsaspartofitsbusinessstrategyandtheriskthatGileadmaynotbe able to complete any such transaction in a timely manner or at all,including the possibility that a governmental entity or regulatory body may delay or r

5、efuse to grant approval for theconsummation of the transaction;Gileads ability to initiate,progress or complete clinical trials within currently anticipated timeframes or at all,the possibility of unfavorable results from ongoingand additional clinical trials and the risk that safety and efficacy da

6、ta from clinical trials may not warrant further development of Gileads product candidates or the product candidates of Gileadsstrategic partners;Gileads ability to submit new drug applications for new product candidates or expanded indications in the currently anticipated timelines;Gileads ability t